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Objectives: Hemodynamic vulnerability after the Norwood procedure for hypoplas-
tic left heart syndrome results from impaired myocardial function, and critical
inefficiency of parallel circulation. Traditional management strategies have at-
tempted to optimize circulatory efficiency by using arterial oxygen saturation
(SaO2) as an index of pulmonary/systemic flow balance, attempting to maintain
SaO2 within a theoretically optimal critical range of 75% to 80%. This optimal range
of SaO2 has not been verified clinically, and strategies targeting SaO2 may be
limited by the fact that SaO2 is a poor predictor of systemic oxygen delivery. We
have previously reported higher venous saturation (SvO2), lower arteriovenous oxygen
content difference, lower systemic vascular resistance, lower pulmonary/systemic flow
ratio, and improved survival with the perioperative use of phenoxybenzamine and
continuous monitoring of SvO2. In this investigation, we tested the hypothesis that
intense afterload reduction with phenoxybenzamine would modify the SvO2-SaO2
relationship by preventing deterioration of systemic oxygen delivery at high SaO2.
Methods: Seventy-one consecutive neonates undergoing the Norwood procedure
with and without phenoxybenzamine were studied. Perioperative hemodynamic
management targeted SvO2 greater than 50%. Hemodynamic data were prospec-
tively acquired for 48 hours postoperatively and analyzed to assess the effect of
phenoxybenzamine on the relationship between SaO2 and SvO2 and other hemo-
dynamic indices. Sixty-two patients received phenoxybenzamine 0.25 mg/kg on
cardiopulmonary bypass; 9 who did not served as controls.
Results: In control patients, SvO2 peaked at an SaO2 of 77%, with reduced SvO2 at
SaO2  85% and SaO2  70% (P  .01), while arteriovenous oxygen content
difference increased with SaO2 greater than 80% (P  .001). In patients receiving
phenoxybenzamine, the SvO2 increased linearly with SaO2 greater than 65% (P 
.001), and arteriovenous oxygen content difference was constant at all SaO2 (P 
ns). The SvO2 was higher, and the arteriovenous oxygen content difference lower,
across the whole SaO2 range with phenoxybenzamine (P  .0001).
Conclusions: A critical range of SaO2 for optimizing systemic oxygen delivery was
confirmed in control patients, and was effectively eliminated by phenoxybenzamine,
specifically by eliminating the systemic hypoperfusion associated with high SaO2.
This effect allows higher SaO2 to be included in a rational hemodynamic strategy to
improve systemic oxygen delivery in the early postoperative management of pa-
tients receiving intense afterload reduction with phenoxybenzamine. The predict-
ability of SvO2 from SaO2 is low in both groups, emphasizing the importance of
SvO2 measurement in these patients.
From the Departments of Anesthesiology,a
Pediatric Critical Care Medicine,b Cardio-
thoracic Surgery,c and Pediatric Cardiolo-
gy,d Children’s Hospital of Wisconsin,e and
the Medical College of Wisconsin,f Mil-
waukee, Wis.
Presented in part at the annual meeting of
the American Society of Anesthesiologists,
New Orleans, La, October 2001.
Received for publication March 18, 2003;
revisions requested April 22, 2003; revi-
sions received May 19, 2003; accepted for
publication June 18, 2003.
Address for reprints: George Hoffman,
MD, Pediatric Anesthesiology and Critical
Care Medicine, Children’s Hospital of Wis-
consin, #735, 9000 West Wisconsin Ave,
Milwaukee, WI 53226 (E-mail: ghoffman
@mcw.edu).
J Thorac Cardiovasc Surg 2004;127:738-45
0022-5223/$30.00
Copyright © 2004 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/S0022-5223(03)01315-1
Surgery for Congenital Heart Disease Hoffman et al
738 The Journal of Thoracic and Cardiovascular Surgery ● March 2004
CH
D
Cardiogenic shock remains a major cause ofmorbidity after the Norwood procedure.Following the Norwood procedure, the ne-onate has a unique convergence of physi-ologic vulnerabilities: myocardial dysfunc-tion after ischemia, reperfusion, and
cardiopulmonary bypass (CPB), potential limitations of a
morphologically right ventricle, potential aorta-coronary
flow limitation, and intrinsic inefficiency of parallel circu-
lation.1,2 Management of the interactions of these multiple
vulnerabilities in the postoperative period is complex and
has been approached both theoretically via circulatory mod-
els and empirically by direct measurement of additional
physiologic parameters such as systemic venous saturation
(SvO2)1,3,4 in an attempt to avoid or detect hemodynamic
deterioration before cardiovascular collapse.
Several models with differing assumptions about com-
plex univentricular circulation have been developed to
guide management when clinical data are incomplete. Nor-
wood and colleagues1,2,5 have argued that maintenance of
arterial saturation (SaO2) in the 75% to 80% range would
optimize circulatory efficiency with a resulting SvO2 of
50% to 60% and pulmonary/systemic flow ratio (Qp/Qs)
near 1.0. This management strategy is based largely on
circulatory modeling with a constant arteriovenous oxygen
content difference, but highly variable Qp/Qs and therefore
SaO2.1,2,5,6 Alternatively, the SaO2-SvO2 relationship has
been modeled at constant total cardiac output, with variable
Qp/Qs and systemic flow, also resulting in a narrow opti-
mum range of SaO2 to maximize SvO2 or systemic oxygen
delivery.6 In either case, the circulatory models predict a
critical range of SaO2 for optimal circulatory efficiency, but
the exact target SaO2 remains dependent on other parame-
ters such as oxygen consumption (VO2), cardiac output, and
hemoglobin, as well as knowledge of Qp/Qs to fully resolve
the resulting SvO2.6 Strategies to balance the circulation
have typically relied on manipulation of medical gases to
raise pulmonary vascular resistance (PVR) and restrict SaO2
to the target range of 75% to 80%.1,2,5,7-10
In a less restrictive model assuming complete systemic
and pulmonary mixing, and permitting variability in both
Qp/Qs and total cardiac output, we demonstrated a wide
range of SvO2 at any SaO2, and the essential lack of pre-
dictability of SvO2 from SaO2.11 This theoretical inade-
quacy of SaO2 as a predictor of SvO2, the intrinsic contra-
dictions and complexities of management strategies which
rely on SaO2 limitation as a means of maximizing oxygen
delivery, and less than optimal outcomes using approaches
based on prediction of SvO2 from SaO2, motivated us to
search for a better management method. Direct, continuous
measurement of SvO2 allowed the detection of critical re-
ductions in systemic oxygen delivery and provided addi-
tional data to more closely estimate Qp/Qs and guide sub-
sequent intervention.3,12 We observed wide variability in
SvO2 despite maintenance of SaO2 in the traditional target
range,12,13 emphasizing the dynamic relationships between
reduction in systemic oxygen delivery, reflex elevation in
systemic vascular resistance (SVR), systemic-pulmonary
flow tradeoff, and further reductions in systemic perfusion
with systemic vasoconstriction, which, if unchecked, would
lead to overt failure of systemic perfusion.
We hypothesized that the relevance of increases in SVR
as a cause of instability after the Norwood procedure could
be confirmed by examination of the relationship between
SaO2 and SvO2 for evidence of deterioration of systemic
oxygenation at higher SaO2. In this investigation, we ana-
lyzed our prospectively collected physiologic database to
attempt to confirm the existence of a critical SaO2 range to
maximize SvO2, and to test the hypothesis that this rela-
tionship would be altered by intense afterload reduction
with phenoxybenzamine.
Materials and Methods
Patient Population and Management Strategy
All patients undergoing the Norwood procedure for hypoplastic
left heart syndrome from July 1996 to July 2000 were included in
this study. After appropriate preoperative stabilization, all patients
underwent surgical palliation consisting of anastomosis of the
pulmonary artery to the ascending aorta combined with augmen-
tation of the ascending aorta, transverse arch, and proximal de-
scending aorta with pulmonary homograft, placement of a system-
ic–pulmonary artery shunt (3.0-4.5 mm), and creation of a
nonrestrictive atrial septal defect.12 This procedure was performed
with synthetic opioid-based perioperative anesthesia,14 hypother-
mic CPB with pH-stat blood gas management to facilitate cooling
to a temperature of 26°C, -stat management before and after
circulatory arrest at 16°C to 18°C, and modified ultrafiltration. On
initiation of CPB, phenoxybenzamine 0.25 mg/kg was adminis-
tered to 62 of 71 infants according to a prospective nonrandomized
surgeon-directed protocol with Food and Drug Administration and
institutional review board approval and parental informed consent.
During rewarming, all patients received milrinone 50   kg1
followed by infusions of milrinone at 0.5  · kg1 · min1 and
dopamine at 3  · kg1 · min1. Oximetric catheters (4F OxyCath,
Abbott Laboratories, N Chicago, Ill) were surgically placed in the
superior vena cava (SVC) to allow continuous monitoring of SvO2.
Before separation from CPB, infusions of nitroprusside or norepi-
nephrine were titrated to achieve an approximate SVR index of 12
Wood units (mean arterial pressure of 40 mm Hg at CPB flow
index of 3.2 L/m2/min), and epinephrine was added for additional
inotropic support if necessary. Patients were transported to the
pediatric intensive care unit (ICU) after hemostasis for postoper-
ative management, which included routine delayed sternal closure.
Postoperative management targets included mean arterial blood
pressure (MAP) greater than 45 mm Hg, SvO2 greater than 50%,
SaO2 70% to 85%, and clinical evidence of end-organ function
(urine output of at least 1 mL · kg1 · h1, biochemical evidence
of adequate gluconeogenesis, and behavioral responses after with-
drawal of neuromuscular blockade). Systemic diastolic pressure
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was not specifically targeted unless electrophysiologic evidence of
ischemia was present with continuous ST analysis (Solar 3000,
Marquette Electronics Inc, Milwaukee, Wis). All patients received
continuous fentanyl infusions at 5 to 10 g · kg1 · h1, and
neuromuscular blockade was maintained by vecuronium infusion
until postoperative day 1. A normothermic environment was main-
tained with servo controlled warmers (Ohio Infant Warmer Sys-
tem, Ohmeda Inc, Columbia, Md). Ventilator settings were ad-
justed to maintain arterial normocapnia (PaCO2 35 to 45 mm Hg)
with inflating pressures of 24 to 28 cm H2O, positive end-expira-
tory pressure of 4 to 5 cm H2O, and an FIO2 of 0.3 to 1.0 to assure
fully saturated pulmonary capillary blood.15 Specifically, room air
was not used as a ventilating gas, and FIO2 was adjusted to
maximize SvO2. Low SvO2 (40% or less) with Qp/Qs near 2.0 or
greater was addressed by attempts to lower SVR with additional
analgesia or sedation, nitroprusside, or, in patients who had re-
ceived phenoxybenzamine on CPB, initiation of a phenoxyben-
zamine infusion (0.25 mg/kg per day or 10 g · kg1 · h1). A low
SvO2 with Qp/Qs near 1.0 was addressed by transfusion of red
cells to achieve a hematocrit value in the 45% to 50% range, and
additional inotropic support when necessary.
Monitoring and Data Collection
A prospective perioperative database for all patients undergoing
the Norwood repair for hypoplastic left heart syndrome since July
1996 was maintained for demographic, surgical, and 48-hour post-
operative hemodynamic and laboratory data. Physiologic parame-
ters included invasive arterial (MAP) and atrial pressures (RAP),
arterial saturation (N-200, Nellcor, Haywood, Calif), inspired ox-
ygen and end-tidal carbon dioxide tension, and oximetric SvO2
from the SVC as an approximation of mixed venous saturation.1,16
These parameters were continuously displayed, digitally acquired,
and averaged using either a dedicated personal computer–based
monitoring cart (DAP-102; Microstar Labs, Belleview, Wash;
DasyLab, DasyTec GmBH, Concord, NH) or a multichannel clin-
ical information system (Marquette Solar). Arterial and venous
blood gases and co-oximetry (ABL, Radiometer, Copenhagen,
Denmark) were obtained at clinically appropriate intervals. The
physiologic parameters, laboratory data, ventilator parameters, and
medication infusion rates were recorded hourly for the first 48
postoperative hours with a standardized, prospective data record.
From measurements of SaO2, SvO2, MAP, RAP, and hemo-
globin concentration, hemodynamic and oxygen transport indices
were derived according to standard formulas. These derived pa-
rameters included arteriovenous O2 difference in saturation (Sa-
vO2) and content (Ca-vO2), as well as oxygen extraction ratio
(O2ER, [Sa-vO2]/SaO2), and oxygen excess factor ( SaO2/
[Sa-vO2]), both flow-independent indices of systemic oxygen
status. Pulmonary/systemic flow ratio (Qp/Qs) was calculated from
SaO2 and SvO2 using an assumed pulmonary capillary saturation
of 97%.3,4,12,15 Additional parameters derived from an assumed
oxygen consumption of 160 mL · min1 · m2 13,17-19 included
pulmonary blood flow (Qp), systemic blood flow (Qs), systemic
oxygen delivery (DO2), systemic vascular resistance index
(SVRI), and total pulmonary vascular resistance index (PVRI).
Statistical Analysis
Data were summarized as mean  standard deviation (SD) when
continuous, or number and percent when discrete. Oximetric data
were excluded during extracorporeal membrane oxygenator
(ECMO) support and when the SaO2-SvO2 difference was less
than 8%.13 Exploratory analysis of the SvO2-SaO2 relationship
was performed by locally weighted regression,20 and fractional
TABLE 1. Patient demographics
Control
(n  9)
Phenoxybenzamine
(n  62)
Age (d) 7.2 6.4 6.0 3.3
Weight (kg) 3.7 0.5 3.2 0.6
Preoperative mechanical
ventilation
6/9 (67%) 46/62 (75%)
Preoperative inotropic support 4/9 (44%) 29/62 (47%)
Aortic atresia 4/9 (44%) 35/62 (56%)
AAO diameter (mm) 3.33 0.88 3.11 1.31
CPB time (min) 157 70 125 52
DHCA time (min) 64 13 62 14
Shunt diameter (mm) 3.94 0.47 3.67 0.36
Normallized shunt size
(mm2/kg)
3.50 0.83 3.43 0.47
ECMO 1/9 (11%) 1/62 (2%)
Death
Early 0/9 (0%) 3/62 (5%)
Late 3/9 (33%) 14/62 (22%)
Data are expressed as mean  standard deviation or N and %. No
significant differences between groups exist for demographic, preopera-
tive, and operative factors. AAO, Ascending aortic diameter; CPB, cardio-
pulmonary bypass; DHCA, deep hypothermic circulatory arrest; ECMO,
extracorporeal membrane oxygenation.
Figure 1. The distribution of arterial and venous saturation values
found over first 48 hours in all patients is shown. SaO2 (mean 77.9,
SD 5.5) was more tightly controlled than SvO2 (mean 54.9, SD
10.7). Approximately 26% of the measured values for SvO2 were
less than thetarget of 50%, and 1.8% were less than the anaerobic
threshold of 30% (shaded area).
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polynomial regression models were fit for each group. The data
were subsequently partitioned into 6 equal-width strata of SaO2
values from 65% to 90% for quantitative analysis. A 2-way re-
peated-measures analysis of variance (ANOVA) model was used
to test for differences in hemodynamic parameters across intervals
of SaO2, to test for the effect of phenoxybenzamine, and for the
interaction of phenoxybenzamine on the SaO2 effect. Potential
confounding differences in other vasoactive drug doses, FIO2, and
shunt size, were addressed by entry of these parameters into the
model as noninteracting covariates. Post-hoc tests of differences at
high SaO2 were performed with Tukey’s wholly significant differ-
ence (WSD) correction for multiple comparisons, with significance
cutoff at P  .05 after correction. All analysis was performed with
Stata statistical software (StataCorp, College Station, Tex).
Results
Data from 71 patients comprising 2820 patient-hours (mean
40, median 47, range 6 to 48 hours/patient) were analyzed.
There were no significant demographic differences between
patients managed with phenoxybenzamine (n  62) or
without (n  9; Table 1). Two patients were placed on
ECMO support within the first 48 hours for SvO2 below
25%, metabolic acidosis, and impending cardiovascular col-
lapse, one of whom survived; the overall hospital survival
for patients in this study was 68 of 71 or 95.7%.
The distributions of SvO2 and SaO2 reveal a distinct tail
at the lower range for SvO2 (Figure 1). Variation in SvO2
Figure 2. The relationship between SvO2 and SaO2 over the first 48 hours is shown for patients managed with and
without phenoxybenzamine. Hourly data and fitted fractional polynomial regression lines with 95% prediction
intervals are shown for the control (left panel, n  307) and phenoxybenzamine (right panel, n  2513) groups; the
SvO2-SaO2 relationship was distinctly different between groups, as shown by fitted fractional polynomial equa-
tions. The SvO2 peaked at SaO2 of 77% in control patients, but continuously increased as SaO2 increased in
phenoxybenzamine patients.
TABLE 2. Venous saturation at intervals of arterial saturation, and effect of phenoxybenzamine*
SaO2 range Control Phenoxybenzamine Difference P value
65% 40.0 9.2 (36.4–43.7) 40.9 9.0 (38.7–43.2) 0.9 (5.0–6.8) ns
65–70% 41.5 12.5 (38.5–44.3) 46.6 8.7 (45.2–47.9) 5.1 (0.9–19.4) 0.0001
71–75% 46.4 12.3 (44.8–48.1) 51.5 7.4 (50.8–52.3) 5.1 (2.7–7.5) 0.0001
76–80% 50.6 11.9 (48.9–52.5) 56.1 7.7 (55.6–56.6) 5.5 (3.1–17.7) 0.0001
81–85% 46.6 9.3 (43.9–49.3) 59.5 8.2 (58.9–60.1) 12.9 (9.6–16.2) 0.0194
85% 40.2 7.3 (35.2–45.2) 65.6 9.1 (64.4–66.8) 25.4 (19.2–31.6) 0.0035
Data are mean, standard deviation, and 95% confidence intervals for SvO2 at intervals of SaO2. The SvO2 peaked with SaO2 in the 76% to 80% range in
control patients, but continued to increase at higher SaO2 in patients receiving phenoxybenzamine. Differences were tested by the Tukey WSD method
after 2-way repeated-measures analysis of variance. There was a progressive increase in the difference between groups as SaO2 increased (P  .0001
by test for trend).
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was much greater than in SaO2 (SD 10.7 vs 5.5, P .0001).
Despite management directed at maintaining SvO2 greater
than 50%, actual SvO2 was less than the target for 758/2820
hours or 26.8% of the time, and was less than the reported
anaerobic threshold of 30%13 for 52 of 2820 hours or 1.8%
of the time. For the 2768 hours without profound venous
desaturation, the SaO2 was out of the usual target range of
70% to 85% for 374 hours or 13.5% of the time. During the
periods of hemodynamic deterioration and anaerobic risk,
the SaO2 was in the target range of 70% to 85% for 27 of 52
hours or 52% of the time. Thus, detection of hemodynamic
risk by high or low SaO2 was poor, with a sensitivity of
48%, specificity of 84%, and positive predictive value of
only 5%.
The fitted fractional polynomial regressions between
SvO2 and SaO2 showed distinctly different patterns in the
control and phenoxybenzamine groups:
control: SvO2  49 0.064  77 SaO2	2
R2 0.21, P  .0001
phenoxybenzamine: SvO2  0.94  SaO2  17
R2  0.32, P .0001
In control patients, the SvO2-SaO2 relationship showed
reduction of SvO2 at both high and low SaO2, with a peak
at SaO2 of 77%, in an inverse-square pattern. In patients
receiving phenoxybenzamine, the relationship between
SvO2 and SaO2 was continuously and linearly positive over
the range of SaO2 from 60% to 90%. The mean predictive
error was greater in control than phenoxybenzamine groups
(11.5% vs 8.3%, P  .001). The actual data and fitted
equations are shown in Figure 2.
The SaO2-SvO2 relationship was quantitatively assessed
(Table 2). In control patients, this relationship was in fact
convex, with maximal SvO2 occurring at an SaO2 of 75% to
80%, and with reduced SvO2 at SaO2  85% and SaO2 
70% (P  .01), while in patients receiving phenoxyben-
zamine, the SvO2 increased linearly with SaO2  65% (P
.001; Figure 3). In control patients, Ca-vO2 increased with
SaO2  80% (P  .001), while in patients receiving phe-
noxybenzamine, Ca-vO2 was constant at all SaO2 (P 
not significant; Figure 3). The SvO2 was higher, and the
Ca-vO2 lower, across the whole SaO2 range with phe-
noxybenzamine (P  .0001), and the difference in SvO2
between groups increased progressively as SaO2 increased
(P  .0001 by test for trend).
Hemodynamic indices and treatments are summarized in
Table 3. SVR was lower in the phenoxybenzamine group,
despite higher nitroprusside doses in the control group and
higher norepinephrine doses in the phenoxybenzamine
group. Most hemodynamic parameters showed significant
variation across intervals of SaO2, and differences between
treatment groups at high SaO2 were significant for SvO2
(P  .0005), MAP (P  .0005), Qp/Qs (P  .0005), SVRI
(P  .0005), PVRI (P  .0005), and indices of oxygen
delivery (P  .005). Patients receiving phenoxybenzamine
had preservation of systemic oxygen delivery at high SaO2
by stabilization of SVRI, resulting in more balanced Qp/Qs,
and a stable reduction in MAP (Figure 4).
Discussion
The relationship between SaO2 and SvO2 is a complex
function of total cardiac output, Qp/Qs, hematocrit, pulmo-
Figure 3. The means and 95% confidence intervals (CI) of SvO2
and Ca-vO2 at intervals of SaO2 is shown for control and
phenoxybenzamine groups. The SvO2 was higher with phenoxy-
benzamine across the whole range (P < .02); the SaO2 effect was
highly significant (P < .0001). The Ca-vO2 was lower with
phenoxybenzamine across the whole range (P < .001); the SaO2
effect was highly significant (P < .0001). With phenoxyben-
zamine, the Ca-vO2 did not vary with SaO2 (P  not significant).
Significance was assessed by 2-way repeated measures analysis
of variance with adjustment for differences in hemoglobin, FIO2,
PaCO2, shunt size, and doses of dopamine, milrinone, epinephrine,
norepinephrine, and nitroprusside as covariates. Significant dif-
ferences between groups by Tukey WSD post-tests at each SaO2
interval are signified by *.
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nary venous saturation, and oxygen consumption. The data
provide direct, clinical evidence to validate theoretical mod-
els of the critical Qp/Qs and cardiac output dependence of
patients after the Norwood operation. The occurrence of
systemic vasoconstriction in response to falling systemic
perfusion, which will only worsen systemic perfusion in
patients with ventricular dysfunction and aortopulmonary
runoff, was evident at SaO2 above 80% in patients managed
without phenoxybenzamine-mediated afterload reduction.
This situation has traditionally been managed by manipula-
tion of medical gases to raise PVR and lower SVR, using
SaO2 as a rough index of Qp/Qs balance. In control patients,
our data confirm the hypothetical deterioration of systemic
oxygen delivery associated with high SaO2, characterized
by a dramatic increase in SVR, reduction in cardiac output,
and increase in Qp/Qs. The reduction in cardiac output
exceeded the increase in SaO2 as predicted by modeling,21
since indices of systemic oxygen delivery fell. Thus, vari-
able Qp/Qs in control patients resulted in a critical range of
SaO2 associated with maximum SvO2.
In contrast, patients receiving afterload reduction with
phenoxybenzamine did not demonstrate this hemodynamic
deterioration at high SaO2, instead demonstrating a rela-
tively constant arterial pressure, low SVR, and less variabil-
ity in Qp/Qs. The hemodynamics in patients receiving phe-
noxybenzamine tended to behave as predicted by models
with constant Qp/Qs and a variable total cardiac output,
with both SaO2 and SvO2 increasing with cardiac output.
The clinical effect was that SaO2 as high as 90% was not
associated with deterioration in SvO2. Thus, high SaO2
resulted, not from high Qp/Qs but from higher cardiac
output, in the phenoxybenzamine group. The increasing
difference between groups at increasing SaO2 provides
strong evidence for a fundamental alteration in the circula-
tory determinants of SaO2 and SvO2.
Errors in derived indices such as Qp/Qs and SVRI may
result from the limitations imposed by assumptions of pul-
monary vein saturation15 and oxygen consumption.17,18 We
specifically did not wean FIO2 to limit SaO2 and would
attempt to reduce work of breathing in unparalyzed patients
with low SvO2 by sedation and ventilator adjustment. No
further benefit of pharmacologic paralysis on oxygen con-
sumption has been demonstrated,19 and no systematic de-
viations in this clinical approach were evident between
TABLE 3. Average 48 hour hemodynamic indices and support: Effects of arterial saturation and phenoxybenzamine
Parameter
Treatment group ANOVA factors Post-test
Control
(n  9)
Phenoxybenzamine
(n  62) Phenoxybenzamine
SaO2
interval
Difference at
SaO2 > 80%
FIO2 0.41 0.14 (0.33–0.50) 0.36 0.12 (0.33–0.39) *
PaCO2 (mm Hg) 39.3 7.7 (36–42) 41.9 6.9 (41–43) *
Hemoglobin (gm/dL) 16.0 2.0 (15.2–16.9) 15.1 1.5 (14.8–15.4) * ‡
SaO2 (%) 75.3 5.7 (72–79) 78.2 5.4 (77–79) ‡ ‡
Heart rate (min1) 175 16.6 (164–186) 169 17.7 (165–173)
Right atrial pressure, mean (mm Hg) 10.4 1.9 (8.7–12.1) 10.2 2.7 (9.6–10.7) *
Systemic pressure, mean (mm Hg) 55.4 6.9 (52–58) 51.3 5.6 (50–52) * ‡
SvO2 (%) 46.7 11.9 (41–53) 56.2 9.4 (54–58) † ‡ ‡
Qp/Qs 1.49 1.0 (1.15–1.83) 1.30 0.7 (1.18–1.41) † ‡
Sa-vO2 (%) 28.6 12.4 (24–33) 22.1 7.9 (20–24) * † ‡
Ca-vO2 (mL/dL) 6.1 2.7 (5.1–7.1) 4.5 1.6 (4.1–4.8) † † ‡
DO2 (mL · min
1 · m2) 38.4 18.1 (27–50) 49.2 19.0 (45–53) ‡
O2 extraction ratio 0.38 0.16 (0.32–0.44) 0.28 0.10 (0.26–0.31) * ‡
Qs (L · min1 · m2) 3.19 1.45 (2.26–4.12) 4.21 1.66 (3.89–4.54) * * †
Qp (L · min1 · m2) 3.72 1.09 (2.77–4.68) 4.72 1.72 (4.40–5.06) ‡ *
SVRI (Wood units) 17.7 9.7 (15.0–20.5) 11.3 4.2 (10.3–12.2) ‡ * ‡
PVRI (Wood units) 12.8 3.4 (11.1–14.5) 9.6 2.9 (9.0–10.2) † ‡ *
Dopamine (g · kg1 · min1) 5.2 3.0 (4.2–6.2) 3.2 1.2 (2.9–3.6) *
Milrinone (g · kg1 · min1) 0.57 0.18 (0.44–0.69) 0.57 0.22 (0.52–0.61) *
Epinephrine (g · kg1 · min1) 0.14 0.13 (0.10–0.20) 0.07 0.08 (0.05–0.09) * ‡
Norepinephrine (g · kg1 · min1) 0.0 0.0 (0.0) 0.05 0.09 (0.03–0.07) * *
Nitroprusside (g · kg1 · min1) 0.95 0.95 (0.43–1.46) 0.27 0.73 (0.08–0.45) * *
POB total dose (mg/kg) 0.0 0.0 (0.0) 0.37 0.12 (0.34–0.39) ‡
Data are expressed as mean  standard deviation and (95% confidence intervals). Results of a nested, repeated-measures analysis of variance model
(significance of the main effects phenoxybenzamine and SaO2 interval, and difference between treatment groups at SaO2  80% as post-test) for each
parameter are presented as *P  .05; †P  .005; ‡P  .0005. FIO2, Fraction concentration of inspired oxygen; PaCO2, arterial partial pressure of carbon
dioxide; Qp/Qs, pulmonary/systemic flow ratio; Ca-vO2, arteriovenous oxygen content difference; Sa-vO2, arteriovenous oxygen saturation difference;
DO2, systemic oxygen delivery; Qs, systemic blood flow; Qp, pulmonary blood flow; SVRI, systemic vascular resistance index; PVRI, pulmonary vascular
resistance index.
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groups. Neither of these factors would change the primary
finding of the alteration SaO2-SvO2 relationship by phe-
noxybenzamine.
Although the analysis of clinical data in this study is
unique, the early patients in this study have been the sub-
jects of prior investigation.12,13 Differential expansion of
the size of the treatment group has occurred because we
have since administered phenoxybenzamine for all Nor-
wood procedures, except for 2 patients without parental
consent for phenoxybenzamine; the resulting imbalance in
group size would only reduce the power to detect a statis-
tically significant pharmacologic effect. Because phenoxy-
benzamine was administered without randomization, the
differences between treatment groups could result from
existing differences in integrated cardiovascular reflex re-
sponses or in treatment variables between patients. How-
ever, the groups were highly similar in all factors except for
the use of phenoxybenzamine, and the different patterns of
response persisted after controlling for differences in other
treatment variables.
With continuous recordings of oximetric SvO2 in the
acute postoperative period, we have demonstrated rapid
deterioration in SvO2 associated with systemic vasocon-
striction in patients not receiving phenoxybenzamine.12
Since norepinephrine is the postganglionic sympathetic neu-
rotransmitter, -adrenergic blockade would be expected to
blunt the profound sympathetic vasomotor responses ob-
served in high-risk neonates undergoing complex cardio-
vascular procedures.14 Although other drugs may be as
effective as phenoxybenzamine in reducing SVR under rest-
ing conditions, we did not achieve similar results in the
control group with routine use of milrinone and sodium
nitroprusside.
The perioperative medical management of these patients
requires synthesis of information from multiple sources to
derive management decisions, which may involve compro-
mise between competing goals. Our vasoactive drug strat-
egy used milrinone for post- receptor amplification of
inotropy and vasodilation, and dopamine for dopaminergic
effects only. A fixed dose of phenoxybenzamine was ad-
ministered on CPB to all patients in the phenoxybenzamine
group to block -adrenergic vasoconstriction, and titration
of short-acting drugs to modify SVR was necessary. We
used epinephrine and norepinephrine liberally to modify
SVR and to provide potent inotropy, and occasionally added
low-dose nitroprusside for additional vasodilation. We
added an infusion of phenoxybenzamine in 46 of 62 patients
in the phenoxybenzamine group if the postoperative hemo-
dynamic pattern showed a need for more consistent SVR
reduction. Through multiple stepwise manipulations, the
medication mixture could become complex in some pa-
tients, and this study did not specifically address strategies
to simplify vasoactive drug use. However, our data suggest
that -adrenergic blockade is a more effective approach to
modify the intense sympathetically mediated vasomotor re-
sponses in these infants, and the use of a very long-acting
drug like phenoxybenzamine commits the patient to a treat-
ment strategy based on sustained SVR reduction. Optimi-
zation of hemodynamics by control of SVR, as predicted in
Figure 4. The means and 95% confidence intervals of MAP, Qp/
Qs, and SVRI at intervals of SaO2 in control and phenoxyben-
zamine groups. The MAP, Qp/Qs, and SVRI were lower with
phenoxybenzamine across the whole range (P < .001); the SaO2
effect was highly significant (P < .0001). Significant differences
between groups by Tukey WSD after 2-way repeated measures
analysis of variance at each SaO2 interval are indicated by *.
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a mathematical model of post-Norwood circulation,22 was
confirmed by our data.
The data also provide direct evidence of the poor pre-
dictive value of SaO2 for systemic oxygen delivery, as
predicted from theoretical models,11,21-23 and emphasizing
the importance of continuous SvO2 monitoring11-13 to indi-
cate systemic oxygen status. A priori, we did not anticipate
any predictable relationship between SaO2 and SvO2; in-
stead, we relied on continuous SvO2 measurement to guide
management aimed at provision of adequate oxygen deliv-
ery. Even in the phenoxybenzamine group, only 32% of the
SvO2 variance could be explained by SaO2; therefore, we do
not advocate acute postoperative management of these pa-
tients without SvO2 monitoring.
The findings of the current study support management
strategies based on the measurement and maximization of
SvO2, given the poor predictive value of SaO2 for SvO2.
The data provide support both for management strategies
such as intentional hypercapnia24 to raise PVR when SVR is
relatively uncontrolled, and for pharmacologic control of
SVR with phenoxybenzamine. With the latter strategy,
higher SaO2 is not deleterious, and is typically associated
with improved systemic oxygen delivery.
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